Skip to main content
رجوع
Watch Compare

Nuvectis Pharma, Inc.

جودة البيانات: 83%
NVCT
Nasdaq Manufacturing Chemicals
KWD 8.22
▲ KWD 0.06 (0.74%)
القيمة السوقية: 216.17 M
السعر
KWD 8.16
القيمة السوقية
216.17 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Negative free cash flow of -16.01 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-129.36%
أقل من متوسط القطاع (-53.41%)
ROIC-106.57%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio3.07
Interest CoverageN/A

التقييم

PE (TTM)
-8.18
أقل من متوسط القطاع (-1.48)
P/B Ratio9.00
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -8.2 -1.5
P/B 9.0 1.6
ROE % -129.4 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

IRSIX IRSIX
0.00% weight
IIRSX IIRSX
0.00% weight
IRCIX IRCIX
0.00% weight
VVICX VVICX
0.00% weight
IRSSX IRSSX
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -26.44 M
ROE -129.36% ROA -84.49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -16.01 M
ROIC -106.57% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.07
Interest Coverage N/A Asset Turnover N/A
Working Capital 24.01 M Tangible Book Value 24.01 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8.18 Forward P/E N/A
P/B Ratio 9.00 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7.41%
Market Cap 216.17 M Enterprise Value 180.73 M
Per Share
EPS (Diluted TTM) -1.32 Revenue / Share N/A
FCF / Share -0.60 OCF / Share -0.60
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 60.54%
SBC-Adj. FCF -21.83 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -26.44 M -19.00 M -22.26 M -19.09 M
EPS (Diluted) -1.32 -1.11 -1.43 -1.51
Gross Profit — — — —
Operating Income -27.57 M -19.85 M -22.90 M -19.23 M
EBITDA — — — —
R&D Expenses 18.15 M 12.92 M 15.38 M 13.23 M
SG&A Expenses — — — —
D&A — — — —
Interest Expense — — — —
Income Tax — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 31.71 M 18.61 M 19.19 M 20.41 M
Total Liabilities 13.30 M 8.89 M 6.98 M 6.19 M
Shareholders' Equity 18.41 M 9.71 M 12.20 M 14.22 M
Total Debt — — — —
Cash & Equivalents 31.63 M 18.53 M 19.13 M 19.99 M
Current Assets 31.71 M 18.61 M 19.19 M 20.41 M
Current Liabilities 13.30 M 8.89 M 6.98 M 6.19 M